Table 2. Summary of reports on G-CSF producing UCC.
Table 2. Summary of reports on G-CSF producing UCC.
Table 2. Summary of reports on G-CSF producing UCC.
Table 2. Summary of reports on G-CSF producing UCC.
Table 2. Summary of reports on G-CSF producing UCC.
Table 2. Summary of reports on G-CSF producing UCC.
Table 2. Summary of reports on G-CSF producing UCC.
Table 2. Summary of reports on G-CSF producing UCC.
Table 2. Summary of reports on G-CSF producing UCC.
Table 2. Summary of reports on G-CSF producing UCC.
Table 2. Summary of reports on G-CSF producing UCC.
Table 2. Summary of reports on G-CSF producing
UCC.
Age
Stage
Histology
G-CSF
(pg/ml)
WBC
(x103/ul)
CRP
(mg/dl)
Initial Tx
PFS (M)
Rec site
Rec Tx
OS (M)
Reference
56
IB2
Sq
197
12.9
7.0
Surgery
0.5
Parametrium
BSC
2
6
39
IB2
Sq
50
13.9
1.8
Surgery-RT
0.25
Brain, skin, lung
CT
5
7
72
IB2
Sq
248
20.6
4.8
CCRT
6
Uterus. lung
S-CT
15
7
64
IIA2
Cs
1500
48.0
NA
RT
0.25
Skin, bone
RT
2
8
64
IIB
Ad
148
11.8
3.8
RT
0.25
SCLN, liver,lung
BSC
3
9
43
IIB
Sq
323
28.3
6.2
CCRT
2
SCLN, liver,lung
BSC
5
Present case
58
IIB
Sq
58
22.5
6.6
CCRT
NA
NA
NA
24
10
75
IIB
NA
223
31.7
2.6
CIRT
-
-
-
108+
11
41
IIIB
Sq
106
34.4
1.5
CCRT
3
Liver
CT
9
7
76
IIIB
Sq
642
31.1
5.4
CIRT
-
-
-
30+
11
71
IIIB
Sq
195
30.0
NA
RT
-
-
-
8+
12
59
IVB
Sq
875
13.7
0.6
RT-AC
1
Lung, LN
BSC
3
7
70
IVB
Sm
269
17.1
0.8
CT-RT-CT
0
Liver
BSC
11
13
G-CSF, granulocyte-colony stimulating factor; UCC, uterine cervical
cancer; Sq, squamous cell carcinoma; Cs, carcinosarcoma; Ad,
adenocarcinoma; NA, not available; Sm, small cell carcinoma; WBC, white
blood cell count before initial treatment; CRP, serum C-reactive protein
before initial treatment; Tx, treatment; RT, radiotherapy; CCRT,
concurrent chemo-radiotherapy; CIRT, carbon ion radiotherapy; CT,
chemotherapy; PFS, progression free survival; M, months; Rec,
recurrence; LN, lymph node; SC, supraclavicular; BSC, best supportive
care; OS, overall survival; +, still alive. Laboratory test results
before initial treatment are shown.
G-CSF, granulocyte-colony
stimulating factor; UCC, uterine cervical cancer; Sq, squamous cell
carcinoma; Cs, carcinosarcoma; Ad, adenocarcinoma; NA, not available;
Sm, small cell carcinoma; WBC, white blood cell count before initial
treatment; CRP, serum C-reactive protein before initial treatment; Tx,
treatment; RT, radiotherapy; CCRT, concurrent chemo-radiotherapy; CIRT,
carbon ion radiotherapy; CT, chemotherapy; PFS, progression free
survival; M, months; Rec, recurrence; LN, lymph node; SC,
supraclavicular; BSC, best supportive care; OS, overall survival; +,
still alive. Laboratory test results before initial treatment are shown.
G-CSF, granulocyte-colony stimulating factor; UCC, uterine cervical
cancer; Sq, squamous cell carcinoma; Cs, carcinosarcoma; Ad,
adenocarcinoma; NA, not available; Sm, small cell carcinoma; WBC, white
blood cell count before initial treatment; CRP, serum C-reactive protein
before initial treatment; Tx, treatment; RT, radiotherapy; CCRT,
concurrent chemo-radiotherapy; CIRT, carbon ion radiotherapy; CT,
chemotherapy; PFS, progression free survival; M, months; Rec,
recurrence; LN, lymph node; SC, supraclavicular; BSC, best supportive
care; OS, overall survival; +, still alive. Laboratory test results
before initial treatment are shown.
G-CSF, granulocyte-colony
stimulating factor; UCC, uterine cervical cancer; Sq, squamous cell
carcinoma; Cs, carcinosarcoma; Ad, adenocarcinoma; NA, not available;
Sm, small cell carcinoma; WBC, white blood cell count before initial
treatment; CRP, serum C-reactive protein before initial treatment; Tx,
treatment; RT, radiotherapy; CCRT, concurrent chemo-radiotherapy; CIRT,
carbon ion radiotherapy; CT, chemotherapy; PFS, progression free
survival; M, months; Rec, recurrence; LN, lymph node; SC,
supraclavicular; BSC, best supportive care; OS, overall survival; +,
still alive. Laboratory test results before initial treatment are shown.
G-CSF, granulocyte-colony stimulating factor; UCC, uterine cervical
cancer; Sq, squamous cell carcinoma; Cs, carcinosarcoma; Ad,
adenocarcinoma; NA, not available; Sm, small cell carcinoma; WBC, white
blood cell count before initial treatment; CRP, serum C-reactive protein
before initial treatment; Tx, treatment; RT, radiotherapy; CCRT,
concurrent chemo-radiotherapy; CIRT, carbon ion radiotherapy; CT,
chemotherapy; PFS, progression free survival; M, months; Rec,
recurrence; LN, lymph node; SC, supraclavicular; BSC, best supportive
care; OS, overall survival; +, still alive. Laboratory test results
before initial treatment are shown.
G-CSF, granulocyte-colony
stimulating factor; UCC, uterine cervical cancer; Sq, squamous cell
carcinoma; Cs, carcinosarcoma; Ad, adenocarcinoma; NA, not available;
Sm, small cell carcinoma; WBC, white blood cell count before initial
treatment; CRP, serum C-reactive protein before initial treatment; Tx,
treatment; RT, radiotherapy; CCRT, concurrent chemo-radiotherapy; CIRT,
carbon ion radiotherapy; CT, chemotherapy; PFS, progression free
survival; M, months; Rec, recurrence; LN, lymph node; SC,
supraclavicular; BSC, best supportive care; OS, overall survival; +,
still alive. Laboratory test results before initial treatment are shown.
G-CSF, granulocyte-colony stimulating factor; UCC, uterine cervical
cancer; Sq, squamous cell carcinoma; Cs, carcinosarcoma; Ad,
adenocarcinoma; NA, not available; Sm, small cell carcinoma; WBC, white
blood cell count before initial treatment; CRP, serum C-reactive protein
before initial treatment; Tx, treatment; RT, radiotherapy; CCRT,
concurrent chemo-radiotherapy; CIRT, carbon ion radiotherapy; CT,
chemotherapy; PFS, progression free survival; M, months; Rec,
recurrence; LN, lymph node; SC, supraclavicular; BSC, best supportive
care; OS, overall survival; +, still alive. Laboratory test results
before initial treatment are shown.
G-CSF, granulocyte-colony
stimulating factor; UCC, uterine cervical cancer; Sq, squamous cell
carcinoma; Cs, carcinosarcoma; Ad, adenocarcinoma; NA, not available;
Sm, small cell carcinoma; WBC, white blood cell count before initial
treatment; CRP, serum C-reactive protein before initial treatment; Tx,
treatment; RT, radiotherapy; CCRT, concurrent chemo-radiotherapy; CIRT,
carbon ion radiotherapy; CT, chemotherapy; PFS, progression free
survival; M, months; Rec, recurrence; LN, lymph node; SC,
supraclavicular; BSC, best supportive care; OS, overall survival; +,
still alive. Laboratory test results before initial treatment are shown.
G-CSF, granulocyte-colony stimulating factor; UCC, uterine cervical
cancer; Sq, squamous cell carcinoma; Cs, carcinosarcoma; Ad,
adenocarcinoma; NA, not available; Sm, small cell carcinoma; WBC, white
blood cell count before initial treatment; CRP, serum C-reactive protein
before initial treatment; Tx, treatment; RT, radiotherapy; CCRT,
concurrent chemo-radiotherapy; CIRT, carbon ion radiotherapy; CT,
chemotherapy; PFS, progression free survival; M, months; Rec,
recurrence; LN, lymph node; SC, supraclavicular; BSC, best supportive
care; OS, overall survival; +, still alive. Laboratory test results
before initial treatment are shown.
G-CSF, granulocyte-colony
stimulating factor; UCC, uterine cervical cancer; Sq, squamous cell
carcinoma; Cs, carcinosarcoma; Ad, adenocarcinoma; NA, not available;
Sm, small cell carcinoma; WBC, white blood cell count before initial
treatment; CRP, serum C-reactive protein before initial treatment; Tx,
treatment; RT, radiotherapy; CCRT, concurrent chemo-radiotherapy; CIRT,
carbon ion radiotherapy; CT, chemotherapy; PFS, progression free
survival; M, months; Rec, recurrence; LN, lymph node; SC,
supraclavicular; BSC, best supportive care; OS, overall survival; +,
still alive. Laboratory test results before initial treatment are shown.
G-CSF, granulocyte-colony stimulating factor; UCC, uterine cervical
cancer; Sq, squamous cell carcinoma; Cs, carcinosarcoma; Ad,
adenocarcinoma; NA, not available; Sm, small cell carcinoma; WBC, white
blood cell count before initial treatment; CRP, serum C-reactive protein
before initial treatment; Tx, treatment; RT, radiotherapy; CCRT,
concurrent chemo-radiotherapy; CIRT, carbon ion radiotherapy; CT,
chemotherapy; PFS, progression free survival; M, months; Rec,
recurrence; LN, lymph node; SC, supraclavicular; BSC, best supportive
care; OS, overall survival; +, still alive. Laboratory test results
before initial treatment are shown.
G-CSF, granulocyte-colony
stimulating factor; UCC, uterine cervical cancer; Sq, squamous cell
carcinoma; Cs, carcinosarcoma; Ad, adenocarcinoma; NA, not available;
Sm, small cell carcinoma; WBC, white blood cell count before initial
treatment; CRP, serum C-reactive protein before initial treatment; Tx,
treatment; RT, radiotherapy; CCRT, concurrent chemo-radiotherapy; CIRT,
carbon ion radiotherapy; CT, chemotherapy; PFS, progression free
survival; M, months; Rec, recurrence; LN, lymph node; SC,
supraclavicular; BSC, best supportive care; OS, overall survival; +,
still alive. Laboratory test results before initial treatment are
shown.
|
|
|
|
|
|
|
|
|
|
|
|